<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35283326</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1095-953X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>168</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Neurobiology of disease</Title>
          <ISOAbbreviation>Neurobiol Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The roles of connectivity and neuronal phenotype in determining the pattern of α-synuclein pathology in Parkinson's disease.</ArticleTitle>
        <Pagination>
          <StartPage>105687</StartPage>
          <MedlinePgn>105687</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nbd.2022.105687</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0969-9961(22)00078-X</ELocationID>
        <Abstract>
          <AbstractText>Parkinson's disease (PD) is the most common neurodegenerative movement disorder, and motor dysfunction has been attributed to loss of dopaminergic neurons. However, motor dysfunction is only one of many symptoms experienced by patients. A neuropathological hallmark of PD is intraneuronal protein aggregates called Lewy pathology (LP). Neuropathological staging studies have shown that dopaminergic neurons are only one of the many cell types prone to manifest LP. Progressive appearance of LP in multiple brain regions, as well as peripheral nerves, has led to the popular hypothesis that LP and misfolded forms of one of its major components - α-synuclein (aSYN) - can spread through synaptically connected circuits. However, not all brain regions or neurons within connected circuits develop LP, suggesting that cell autonomous factors modulate the development of pathology. Here, we review studies about how LP develops and progressively engages additional brain regions. We focus on how connectivity constrains progression and discuss cell autonomous factors that drive pathology development. We propose a mixed model of cell autonomous factors and trans-synaptic spread as mediators of pathology progression and put forward this model as a framework for future experiments exploring PD pathophysiology.</AbstractText>
          <CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Henderson</LastName>
            <ForeName>Michael X</ForeName>
            <Initials>MX</Initials>
            <AffiliationInfo>
              <Affiliation>Parkinson's Disease Center, Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI 49503, United States of America. Electronic address: michael.henderson@vai.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Henrich</LastName>
            <ForeName>Martin T</ForeName>
            <Initials>MT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Philipps-University Marburg, Marburg 35043, Germany; Department of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg 35043, Germany; Department of Neuroscience, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Geibl</LastName>
            <ForeName>Fanni F</ForeName>
            <Initials>FF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Philipps-University Marburg, Marburg 35043, Germany; Department of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg 35043, Germany; Department of Neuroscience, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oertel</LastName>
            <ForeName>Wolfgang H</ForeName>
            <Initials>WH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Philipps-University Marburg, Marburg 35043, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brundin</LastName>
            <ForeName>Patrik</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Parkinson's Disease Center, Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI 49503, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Surmeier</LastName>
            <ForeName>D James</ForeName>
            <Initials>DJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuroscience, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R33 NS106078</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 DC016519</GrantID>
            <Acronym>DC</Acronym>
            <Agency>NIDCD NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Neurobiol Dis</MedlineTA>
        <NlmUniqueID>9500169</NlmUniqueID>
        <ISSNLinking>0969-9961</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D059290" MajorTopicYN="N">Dopaminergic Neurons</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000080874" MajorTopicYN="Y">Synucleinopathies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Lewy pathology</Keyword>
        <Keyword MajorTopicYN="Y">Neurodegeneration</Keyword>
        <Keyword MajorTopicYN="Y">Propagation</Keyword>
        <Keyword MajorTopicYN="Y">SNCA</Keyword>
        <Keyword MajorTopicYN="Y">Synaptic</Keyword>
        <Keyword MajorTopicYN="Y">Vulnerability</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>14</Day>
          <Hour>5</Hour>
          <Minute>43</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35283326</ArticleId>
        <ArticleId IdType="doi">10.1016/j.nbd.2022.105687</ArticleId>
        <ArticleId IdType="pii">S0969-9961(22)00078-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
